Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice
- 1 August 2011
- journal article
- Published by Elsevier in Laboratory Investigation
- Vol. 24 (8) , 1128-1138
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological featuresLaboratory Investigation, 2010
- Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohortLaboratory Investigation, 2010
- TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinomaLaboratory Investigation, 2009
- TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomasLaboratory Investigation, 2009
- Recurrent gene fusions in prostate cancerNature Reviews Cancer, 2008
- The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell, 2008
- Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancerBritish Journal of Cancer, 2007
- Complex patterns of ETS gene alteration arise during cancer development in the human prostateOncogene, 2007
- Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerOncogene, 2007
- Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancerLaboratory Investigation, 2007